36 results
424B5
BLPH
Bellerophon Therapeutics, Inc.
31 May 23
Prospectus supplement for primary offering
4:40pm
dioxide levels were below the National Ambient Air Quality Standards.
Our technology is based on patents we have exclusively licensed from Ikaria
8-K
EX-99.1
BLPH
Bellerophon Therapeutics, Inc.
5 Jan 22
Company Presentation I January 2022Bellerophon Therapeutics
8:39am
Disease (fILD) Normal IPFCharacterized by variable amounts of inflammation and fibrosis of lung air sacsIdiopathic Pulmonary Fibrosis (IPF) is the most
8-K
EX-99.1
ypxcxfpt6hfff
11 Jan 21
2021 Company Presentation I Company Presentation I January 2021 Bellerophon Therapeutics
8:01am
8-K
EX-10.1
dei5336y
17 Jul 20
Entry into a Material Definitive Agreement
5:01pm
424B5
2ie3 un0xtld
17 Jul 20
Prospectus supplement for primary offering
5:01pm
8-K
EX-1.1
kpvwyzsh7dsnlmxph3v0
20 May 20
Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock
4:04pm
424B5
2wgeed8kkrchges 6q7
20 May 20
Prospectus supplement for primary offering
4:03pm
424B5
6ofb780v k6oh
20 May 20
Prospectus supplement for primary offering
4:02pm
424B5
a44as54 qi9am2kwja
18 May 20
Prospectus supplement for primary offering
4:02pm
424B5
4qbzl
31 Mar 20
Prospectus supplement for primary offering
7:03am
8-K
EX-10.1
fwv gyvlhrqz
30 Mar 20
Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market
4:09pm
8-K
EX-99.1
n9ez6dzx97sjxf 9u
6 Nov 19
Bellerophon Provides Business Update and Reports Third Quarter 2019 Financial Results
8:31am
8-K
EX-99.1
c7vrkbxkj4zm7omp9
16 Sep 19
Bellerophon Receives Orphan Drug Designation for Nitric Oxide in the Treatment of Idiopathic Pulmonary Fibrosis
8:31am